

Title: Amyloid fibril polymorphism in the heart of an ATTR amyloidosis patient with polyneuropathy attributed to the V122 Δ variant

Authors: Yasmin Ahmed^{1§}, Binh An Nguyen^{1§}, Shumaila Afrin¹, Virender Singh¹, Bret Evers^{2,3}, Preeti Singh¹, Rose Pedretti¹, Lanie Wang¹, Parker Bassett¹, Maria del Carmen Fernandez-Ramirez¹, Maja Pekala¹, Barbara Kluge-Beckerman⁴, Lorena Saelices^{1*}

[§]These authors contributed equally

Affiliations:

¹*Center for Alzheimer's and Neurodegenerative Diseases, Department of Biophysics, Peter O'Donnell Jr Brain Institute, University of Texas Southwestern Medical Center (UTSW), Dallas, TX, USA.*

²*Department of Pathology, University of Texas Southwestern Medical Center (UTSW), Dallas, TX, USA.*

³*Department of Ophthalmology, University of Texas Southwestern Medical Center (UTSW), Dallas, TX, USA.*

⁴*Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.*

* Correspondence to: Lorena Saelices Gómez, lorena.saelicesgomez@utsouthwestern.edu

Abstract:

ATTR amyloidosis is a phenotypically heterogeneous disease characterized by the pathological deposition of transthyretin in the form of amyloid fibrils into various organs. ATTR amyloidosis may stem from mutations in variant (ATTRv) amyloidosis, or aging in wild-type (ATTRwt) amyloidosis. ATTRwt generally manifests as a cardiomyopathy phenotype, whereas ATTRv may present as polyneuropathy, cardiomyopathy, or mixed, in combination with many other symptoms deriving from secondary organ involvement. Over 130 different mutational variants of transthyretin have been identified, many of them being linked to specific disease symptoms. Yet, the role of these mutations in the differential disease manifestation remains elusive. Using cryo-electron microscopy, here we structurally characterized fibrils from the heart of an ATTRv patient carrying the V122 Δ mutation, predominantly associated with polyneuropathy. Our results show that these fibrils are polymorphic, presenting as both single and double filaments. Our study alludes to a structural connection contributing to phenotypic variation in ATTR amyloidosis, as polymorphism in ATTR fibrils may manifest in patients with predominantly polyneuropathic phenotypes.

Introduction

Transthyretin amyloidosis (ATTR amyloidosis) is a fatal, phenotypically diverse disease characterized by the deposition of amyloidogenic transthyretin (ATTR) fibrils in various organs. Transthyretin is mainly synthesized by the liver, although other tissues secrete it in lower amounts, including the retinal pigment epithelium and the choroid plexus¹. ATTR deposition may stem from mutations in the *TTR* gene in variant ATTR (ATTRv) amyloidosis, or by unknown aging-related factors in wild-type ATTR (ATTRwt) amyloidosis². While ATTRwt amyloidosis is clinically more predictable, ATTRv amyloidosis often presents with complex and variable clinical manifestations including polyneuropathy, cardiomyopathy, a mixed phenotype, in addition to many other symptoms stemming from secondary organ involvement including carpal tunnel syndrome, gastrointestinal dysfunction, and ocular issues³. More than 130 mutational variants of transthyretin have been documented, with many showing associations for specific disease symptoms⁴. The influence of each mutational variant on the clinical phenotype is not yet fully understood, and some studies suggest that could be related to their effects on fibril formation, structure, or both^{5,6}.

Recent cryo-electron microscopy (cryo-EM) studies have contributed important structural insights into the amyloid assemblies of various diseases⁷⁻⁹. Notably, studies on tau, α -synuclein, amyloid- β , and TDP-43, have all revealed disease-specific fibril polymorphism, in which a particular fibrillar fold is linked to a specific disease¹⁰⁻¹⁴. Exemplifying this phenomenon, Alzheimer's disease patients exhibit the same two types of tau fibrils: paired helical filaments and straight filaments. And yet, these structures differ from the ones adopted by tau in chronic traumatic encephalopathy or other tauopathies¹⁵. Another example is found in amyloid- β filaments from Alzheimer's disease patients. Amyloid- β filaments can adopt several different amyloid folds within the same individual—nonetheless, the structures remain specific to the disease¹³.

In ATTR amyloidosis, cryo-EM investigations have revealed a substantial structural variability whose influence on phenotype remains to be established. The early cryo-EM studies of ATTR fibrils revealed a unique structure conformation, made of two fragments of transthyretin and forming a polar channel that runs through the fibril¹⁶. We and others have found that the amyloid fibrils from multiple ATTRwt amyloidosis patients are structurally homogenous, which is consistent with their more uniform disease presentation with cardiomyopathy^{16,17}. In contrast, our recent study on ATTR fibrils from polyneuropathic ATTRI84S patients reveals an unprecedented structural polymorphism¹⁸. We observed that each of the three patients had two populations of fibrils: one that was shared by all three patients, similar to the one observed in the early studies; and one that was specific to each individual, with local structural variations in the polar channel. The nature and location of the structural variations that we observed suggest that the mutation I84S may drive fibril polymorphism in these patients. Additionally, previous

studies have disclosed that the amyloid fibrils deposited in the heart¹⁶ and the vitreous humor of the eye¹⁹ of ATTRV30M patients can adopt distinct structures. These structures differ at two levels: the conformation of the fibril has local variations in the polar channel and the fibrils have different numbers of protofilaments. These studies suggest that ATTR fibril polymorphism may also stem from the organ of deposition and/or the source of transthyretin. Additional structural investigations are necessary to ascertain the potential role of ATTR fibril polymorphism in clinicopathological heterogeneity, should there be any, and to elucidate the underlying causes of structural variability.

In this study, we used cryo-EM to determine the structure of fibrils extracted from the heart of an ATTRV122 Δ patient²⁰. V122 Δ is the only documented deletion mutation in the *TTR* gene, and manifests predominantly as polyneuropathy, along with cardiomyopathy and carpal tunnel syndrome. Here we show that ATTRV122 Δ cardiac fibrils from a single patient with polyneuropathy are polymorphic, as they can ensemble in bundles made of single and double protofilaments. This study underlines the complexity of the structural landscape in ATTR amyloidosis and calls for further structural studies.

Results

Characterization of ATTR fibrils

Freshly frozen cardiac tissue was obtained from an Ecuadorian male heterozygous carrier of the ATTRV122 Δ variant who became affected in his early 60s and presented with both peripheral neuropathy and autonomic neuropathy²⁰. Sections of the heart show abundant deposits of amyloid within the interstitium of the myocardium, which was confirmed by Congo Red and Thioflavin-S staining (Fig. 1a-c). Examination of the epicardium reveals amyloid deposits within nerves, vessel walls, and adipose tissue (Fig. 1a-c). We isolated the ATTR fibrils from the explanted heart of this patient in accordance with a previously established mild water-based extraction procedure¹⁶. Mass spectrometry analysis confirmed transthyretin protein identity, ATTRV122 Δ genotype, and the presence of both the mutant and wild-type transthyretin protein, as expected from this patient's zygosity (Supplementary Fig. 1). We typed the sample by western blotting using an inhouse antibody that specifically targets the C-terminal fragments of transthyretin (Supplementary Fig. 2a). These fragments are characteristic of type A ATTR fibrils, which are made of both full-length and C-terminal fragmented transthyretin, and distinguishes them from type B ATTR fibrils which are composed of solely full-length transthyretin²¹ (Supplementary Fig. 2a). The typing confirmed that the *ex-vivo* fibril extract from the ATTRV122 Δ patient contained type A ATTR fibrils. We validated the amyloidogenic properties of the sample by examining its capacity to seed recombinant transthyretin aggregation *in vitro* (Supplementary Fig. 2b). We verified the extraction of ATTR fibrils and their suitability

for further cryo-EM analysis by negative stained transmission electron microscopy (Supplementary Fig. 2c).




Figure 1: Histological analysis of ATTRV122 Δ cardiac tissue. Hematoxylin and eosin (H&E), Congo red, and thioflavin-S staining (left to right) of different anatomical features of cardiac tissue, including cardiomyocytes (a), epicardial nerve (b), and epicardial fat. The staining depicts the localization and abundance of transthyretin amyloid deposits. Dark red cardiomyocytes are denoted by black arrows, and the yellow arrows signify amyloid deposits. Scale bars, 300 μ m.

Structural polymorphism in cardiac ATTRV122 Δ fibrils

We carried out cryo-EM analysis to determine the structure of ATTRV122 Δ fibrils. We optimized the fibril concentration and vitrification conditions to ensure optimal fibril distribution for cryo-EM data collection (Supplementary Fig. 2d). Fibrils were auto-picked using Topaz²². Two-dimensional (2D) classification of the collected images yielded multiple distinct morphologies. We identified a minor population (4.34%) of straight fibrils lacking clear twists, as found in previous studies of ATTR fibrils, and thus they were unsuitable for helical reconstruction. The sample also included a major population (\sim 78.72%) of twisted single fibrils, similar in morphology to those found in other ATTR fibril extracts^{16,17,23-25} (Supplementary Table 1). To our surprise, we also found a smaller population (\sim 17%) of twisted double fibrils consisting of two

intertwined protofilaments, which have not been observed in other cardiac ATTR fibrils to date (Fig. 2a, b). These species had distinct fibril widths as shown in Supplementary Fig. 3. We stitched the representative 2D class averages of single and double fibrils to estimate their respective crossover distances (Fig. 2b). We used these initial helical parameters to obtain three-dimensional (3D) classes. The density map of the single fibrils exhibited structural consistency with previously published ATTR fibrils (Fig. 2c)^{17,23,25-27}. Using the 2D classification of the double fibrils, we built one initial model, low-pass filtered to 20 Å, and used that as the reference model for 3D classification (Fig 2b). The reconstruction of double fibrils revealed two distinct classes: one class with an apparent C2 symmetry (herein referred to as C-to-C double fibrils) and a second class with apparent C1 symmetry (herein referred to as N-to-C double fibrils). In both classes, each individual protofilament seemingly adopts the same structural conformation as in the single fibrils, but they differ in the inter-protofilament interface (Fig. 2c).




Figure 2: Cryo-EM data collection and processing of cardiac fibrils from an ATTRV122 Δ patient. **a.** Representative cryo-EM micrographs of single (top) and double (bottom) fibrils. Scale bar, 20 nm. **b.** Representative 2D class averages of single (top) and double (bottom) fibrils extracted at particle box size of 768 pixel. Under the representative individual 2D classes panels, we include the stitching of all 2D classes of single fibril (top) and the initial model of double fibril generated in RELION (bottom). **c.** 3D class averages of single (top) and double (bottom) fibrils.

Structure of the single ATTRV122 Δ fibril closely resembles that of ATTRwt fibrils

We processed the 3D classes with single fibrils and generated a density map at a resolution of 3.6 Å (Supplementary Fig. 4). This fibril structure has a crossover distance of 692 Å, a twist angle of -1.27° (fibril was assumed to have left-handed twist), and a rise of 4.9 Å (Fig. 3a, b). The reconstructed density map resembles the structure of cardiac ATTRwt¹⁷ and several ATTRv^{16,23,24} fibrils previously solved. In detail, the model of ATTRV122Δ model comprises two fragments: a N-terminal fragment spanning from Pro 11 to Lys 35 and a C-terminal fragment spanning from Leu 58 to Thr 122. Each layer of the fibril is stabilized by steric zippers throughout the entire structure, a hydrophobic pocket within the N-terminal fragment (17-LDAVRGSPAI-26), and an aromatic pocket within the C-terminal fragment consisting of Tyr78, Trp79, Phe87 and Phe 95. The residues Leu 58 to Ile 84 form a polar channel with no identifiable elements seen at the current resolution. The fibril structure is stabilized by backbone hydrogen bonds, intra-chain hydrogen bonds, and π - π stacking of aromatics residues. Structural comparison of the C α with published ATTR structures (ATTRwt, ATTRI84S, ATTRV30M, ATTRV20I, ATTRG47E, and ATTRV122I) from previous studies and ATTRV122Δ demonstrates high similarity to ATTRwt structures with a root mean square deviation (r.m.s.d) value of 0.68 Å (Fig. 3c).




Figure 3: Cryo-EM structure of single fibril morphology from an ATTRV122Δ patient. a. Side view of the reconstructed fibril model showing the crossover distance, with the closeup side view of the map depicting the helical rise. **b.** Cryo-EM density and atomic model of the single fibril structure. The models contain two fragments of transthyretin colored blue (residues Pro 11 to Lys 35) and pink (residues Leu 58 to Thr 122). **c.** Structural backbone alignment of ATTRV122Δ (pink) fibrils compared to ATTRwt (green) fibrils and a group of previously

published ATTRv (blue) fibril structures, including ATTRI84S, ATTRV30M, ATTRV30I, ATTRG47E, and ATTRV122I fibrils^{16,17,25}. We have purposefully excluded polymorphic ATTR-I84S fibrils from this alignment because our objective with this analysis is to show the similarity of this particular fibril morphology across multiple genetic backgrounds, with an r.m.s.d. value of 0.68 Å.

CryoEM structure of N-to-C double fibrils

We determined the 3D structure of N-to-C double fibrils to a resolution of 3.7 Å (Supplementary Fig. 4). This structure comprises of two intertwined and staggered protofilaments. Optimal local symmetry search revealed a twist of -1.15° corresponding to a crossover distance of 764 Å (assuming a left-handed twist fibril) and the rise of 4.88 Å (Fig. 4a). Each of the two protofilaments adopts a conformation consistent with the single fibril model with minor modification due to a missing density at the N-terminal end. Thus, compared to the single fibril, the N-terminal fragment of the N-to-C double fibrils' structure appears to be shorter, lacking the residues Pro 11 and Lys 35 (Fig. 4b). The interface of the two protofilaments is held by the hydrogen bonding interactions between Glu 92 to Arg 21' and Asn 98 to Tyr 116' (Fig 4e). To date, cardiac extracts of ATTR fibrils have been found to contain only single fibrils. In contrast, a recent study shows that the extract from the vitreous humor of an ATTRV30M patient can contain fibrils with single, double, and triple protofilaments²⁴. In this study, the authors only determined the structure of the double fibril population; and within this subset, the interprotofilament interactions involve the hydrogen bonding between His 90 to Glu 92' and Glu 92 to His90' (Fig. 4c, e). While the polar channel of N-to-C double fibrils' structure adopts the same conformation as found in ATTRwt fibrils, variations were observed in the polar channel of ATTRV30M double fibrils from vitreous humor. In the latter, the residue Glu 62 flips 180° away from the solution and into the polar channel, and residues Glu 57 to Gly 67 (previously referred to as the polar channel gate) block the polar channel diagonally (Fig 4c, d).




Figure 4: Cryo-EM structure of N-to-C double fibrils' morphology from an ATTRV122Δ patient. **a.** Side view of the reconstructed fibril model of the N-to-C double fibril showing the crossover distance, with the closeup side view of the map depicting the helical rise. **b.** Cryo-EM density map and atomic model of the double fibril. On each protofilament, the model contains two fragments of transthyretin: the N-terminal fragment in blue (Leu 12 to Arg 34, and Pro 11 to Lys 35) and the C-terminal fragment in pink (Leu 58 to Thr 122). The two asymmetrically intertwined protofilaments' interactions are mostly polar. **c.** Structural alignment of ATTRV122Δ (pink) and ATTRV30M eye (green) double fibrils highlighting the contrast of the symmetry of the double fibrils along with difference in residue interactions. **d.** Different arrangement of residues in the polar channel of the fibrils. **e.** Different interactions were observed at the fibrils' interfaces of ATTRV122Δ (pink) and ATTRV30M eye (green).

Cryo-EM structure of C-to-C double fibrils

The C-to-C double fibrils' structure from the ATTRV122Δ amyloidosis patient was resolved at resolution of 4.3 Å (Supplementary Fig. 4). At this resolution, although we cannot see a discernable separation of the density map of individual layers within the fibril, we can identify in cross-sectional top view a two-fold symmetry (C2 symmetry) along the fibril axis. Because of the limited resolution of the density map, we chose not to construct an atomic model for the C-to-C double fibrils. Instead, we docked the model of the single fibril structure into this density map, with a C2 symmetry (Fig. 3b). We found that the predicted residues at the interface of the two fibrils engage in several interactions including two salt bridges between Glu 92 and Arg 104', hydrophobic interactions between Val 94 and Pro 102', and hydrogen bonds between Thr 96 and Ser 100'.




Figure 5: Cryo-EM structure of C-to-C double fibrils from an ATTRv-V122Δ patient. a. Cryo-EM model of the C-to-C double fibrils showing the crossover distance, with the closeup side view of the map depicting the helical rise. **b.** Docking illustrates the cryo-EM density model of the C-to-C double fibrils' morphology showing the asymmetry of the fibrils. **c.** Docking indicating possibly polar interactions of fibrils are highlighted in purple.

The two double fibrils' structures can co-exist within the same fibril.

We also traced the fibril segments that contributed to the different density maps of double fibrils' morphologies present in the ATTRV122Δ cardiac extract, back to their corresponding micrographs. Our finding revealed a coexistence of segments from both N-to-C and C-to-C morphologies within the same fibril (Fig. 6a, b). Although, this phenomenon has been previously observed in published amyloid fibrils including those of systemic AL amyloidosis (subtype λ3 light chain)²⁸ and ATTR amyloidosis (ATTR184S)²³, our study marks the first observation of this phenomenon within double fibrils.




Figure 6: Existence of different morphologies within the same ATTRV122 Δ fibril. a. Representative cryo-EM micrographs of cardiac ATTRV122 Δ single and double fibrils. **b.** Representative cryo-EM micrograph tracing the single fibril (blue arrows), C-to-N double fibrils (purple circles), and C-to-C double fibrils (pink circles) back to the same fibril, indicating that the different morphologies can co-exist within the same fibril. Scale bar, 20 nm.

Discussion

In this study, we determined the structure of *ex-vivo* ATTRV122 Δ amyloid fibrils extracted from the heart of a polyneuropathy patient. We found that these fibrils are polymorphic, as they are comprised of single and double protofilaments, in which each of the protofilaments adopts the same conformation. In conjunction with prior cryo-EM investigations on ATTR fibrils, our current findings open questions about a potential link between fibril structure and phenotype. Does fibril polymorphism play a role in the development of polyneuropathy in ATTR amyloidosis patients? If so, what mechanisms underlie the generation of this structural variability in neuropathy patients?

Early *in-vitro* studies offer the hypothesis that the phenotypic heterogeneity of ATTR amyloidosis may result from the differential effects of mutations in transthyretin aggregation. These studies describe how some pathogenic mutations are more prone to destabilizing the native protein conformation, facilitating tetramer dissociation into monomers and subsequent protein aggregation^{6,29}. Although there are no *in-vitro* studies on the stability of ATTRV122Δ tetramers to date, this variant may potentially be one example of a destabilizing mutation. Visualizing the crystal structure of tetrameric ATTRV122Δ (1bz8) in comparison to wild-type (4tlt), we indeed find an alternative conformation of the β-strand in where the mutation is located. Briefly, the absence of Val122 seems to induce a conformational alteration in subsequent residues at the C-terminal where the glutamines at position 127 reorient towards the transthyretin T4 binding pocket, potentially causing steric hindrance (Supplementary Fig. 4). This hindrance could prevent the binding of T4, destabilizing the unbound transthyretin tetramer and thereby promoting aggregation into amyloid^{29,30}. It is conceivable to connect the differential effect of mutations in tetramer dissociation with the different onsets observed between genotypes. Thus, mutations that would destabilize the tetramer more dramatically, would consequently lead to early onsets than those mutation that are less disruptive. However, the association between this differential destabilization and the genotype-specific organ tropism or the phenotypic variability observed within the same genotype is not so evident and could be explained by other factors.

Cryo-EM studies of amyloid fibrils have yielded near-atomic resolution density maps revealing acute structural insights into amyloid disease pathologies and phenotypes for other conditions. Numerous structural examinations of amyloid fibrils isolated from the brains of patients afflicted with neurodegenerative diseases including tauopathies and synucleinopathies, consistently indicate a link between each phenotype and an amyloid structural fold¹⁰⁻¹⁴. On the contrary, ATTR amyloidosis displays a heterogeneous spectrum of fibril structures that are capable of co-existing within the same individual¹⁸. The most prominent structural differences are found in the number of protofilaments observed within the same fibrils and the conformation adopted by a polar channel that runs along the fibril axis. Regardless, different polymorphs can be found within the same fibril, indicating that they are capable of seeding each other (Fig. 6). The association of these fibril structures with phenotype in ATTR amyloidosis has not been established yet.

With the contribution of our study, we observe that, to date, primarily cardiomyopathic patients have one—and only one—fibril structure in cardiac tissue, whereas primarily polyneuropathic patients present a more variable structural landscape^{16,18,24}. In ATTRwt patients and all primarily cardiomyopathic ATTRv patients, the polar channel appears in a closed state, with the residues 57 to 67 acting as a gate that locks the channel at a hydrophobic interface^{23 16}. In contrast, in primarily polyneuropathic ATTRI84S patients, the gate that closes this channel suffers multiple perturbations, opening, exposing, or blocking the polar channel²³. Additionally, in the eye of

V30M patients, fibrils have multiple protofilaments and the gate is also perturbed¹⁹. Our study on ATTRV122Δ fibrils provides an additional polymorph where the gate remains closed, as shown in fibrils from cardiomyopathic patients, but the fibrils are made of single and double protofilaments, resembling those fibrils found in vitreous humor (Fig. 4c-e). Yet, the interprotofilament interfaces found in cardiac ATTRV122Δ fibrils are not the same as the interface found in ATTRV30M fibrils from the vitreous humor (Fig. 4c-e).

The precise role of ATTR variants in shaping fibril polymorphism remains uncertain and requires further investigation. In the case of ATTRI84S, the mutation of residue 84 to serine could perturb a hydrophobic interface with the gate of the polar channel (around residue glycine 57). This perturbation could destabilize the “lock” of the gate that closes the polar channel, forcing and/or facilitating the formation of alternative gate conformations. However, the ATTRV30M fibrils from the vitreous humor also adopt an alternative gate conformation without seemingly destabilizing the gate lock¹⁹. Thus, the involvement of the V30M mutation in the formation of this alternative gate conformation or the formation of fibrils with multiple protofilaments in vitreous humor is not obvious. Similarly, the influence of the ATTRV122Δ deletion mutation in leading to multiple protofilaments remains unclear as the mutation site on the fibril is distant from any of the two potential interprotofilament interfaces. Instead of *driving* the formation of new conformations, we surmise that the mutation may *allow for* the arrangement of the protofilaments into double fibrils. In other words, the shortening of one residue on the β-strand H of one protofilament could permit the interaction with another protofilament. This may apply to both double fibril morphologies reported from the ATTRV122Δ patient. Taken together, it is still unclear whether the V122Δ mutation impacts tetramer stabilization, drives the formation of particular fibril conformations, and/or affects protein aggregation and phenotype through alternative mechanisms.

Should there be a potential association between fibril polymorphism and polyneuropathy in ATTR amyloidosis, would this polymorphic variation be detectable, or imprinted, within the blood of ATTR patients? Recent studies from the Kelly lab and our lab indicate that transthyretin may aggregate in the blood of ATTR patients. The Kelly lab developed a peptide probe that detects non-native transthyretin species in the blood of neuropathic patients that are absent in those with cardiomyopathic or mixed phenotypes³¹. We, in turn, developed a peptide probe that detects big transthyretin aggregates in the blood of all ATTR patients, regardless of their phenotype³². These observations may implicate that the biology of ATTR amyloidosis with polyneuropathy may be different from that of ATTR amyloidosis with cardiomyopathy or mixed phenotypes. The non-native and aggregated transthyretin species may represent the earliest stages of protein aggregation in ATTR amyloidosis patients, potentially serving as precursors to larger transthyretin amyloid fibrils. In neuropathic cases, the non-native species might serve as or evolve into polymorphic seeds, featuring single or multiple protofilaments. These seeds could then catalyze the polymerization of circulating wild-type and variant transthyretin into fibrils,

also with single or multiple protofilaments, and/or adopting alternative gate conformations. Should this assumption be correct, the next inquiry would revolve around understanding how certain variants—and not others—contribute to the formation of polymorphic non-native transthyretin species or aggregates in the bloodstream.

Our study has the following limitations. Because our biobank of patient samples is limited to the clinical practice of late Dr. Benson, the present study includes the heart of only one patient. Thus, the study of the connection between fibril structure and phenotype would benefit from additional structures derived from multiple organs, particularly those implicated in neuropathy, and/or additional patients. In essence, we cannot conclude that all ATTRV122 Δ fibrils share the same conformations as found in this one patient, as it may vary between individuals. Moreover, these fibrils are isolated at the time of death, thus representing the morphology of the fibrils in the final stage of the aggregation process. Further studies are warranted to understand the relationship between fibril structures and disease phenotypes in ATTR amyloidosis patients.

In summary, we structurally characterized cardiac ATTRV122 Δ fibrils from a polyneuropathy patient. We observed polymorphism within these fibrils, and we determined the structures of both single and double fibril morphologies. Our study suggests that polymorphism in ATTR fibrils may manifest in predominantly polyneuropathic phenotypes. This study contributes to the understanding of the complex mutational landscape of ATTR amyloidosis and calls for further characterization of ATTR fibril polymorphism.

Materials & Methods

Patient description and tissue material

This investigation is based on the study of postmortem cardiac tissue from the explanted heart of one ATTR patient carrying the V122 Δ mutation. This patient was a male, and his symptoms included peripheral neuropathy and autonomic neuropathy (impotence, alternating constipation/diarrhea, urinary frequency). The Office of the Human Research Protection Program exempted the study from Internal Review Board since the specimen was anonymized.

Fibril extraction from human cardiac tissue

Amyloid fibrils were extracted from fresh-frozen human cardiac tissue, following a previously described protocol¹⁶. Briefly, ~150 mg of frozen human tissue was thawed at room temperature, then finely cut into small pieces with a scalpel. The sample was washed with 1 mL Tris-calcium buffer (20 mM Tris, 150 mM NaCl, 2 mM CaCl₂, 0.1% NaN₃, pH 8.0), then centrifuged for 5 min at 3100 x g and 4 °C. The supernatant was removed, and the underwent four additional washes in Tris-calcium buffer. Following the washing steps, the pellet was resuspended in 1 mL

of 5 mg/mL collagenase solution, then incubated overnight at 37 °C, shaking at 400 rpm. The next morning, the resuspension was centrifuged for 30 min at 3100 x g and 4 °C. The pellet was subsequently resuspended in 1 mL Tris-ethylenediaminetetraacetic acid (EDTA) buffer (20 mM Tris, 140 mM NaCl, 10 mM EDTA, 0.1% NaN₃, pH 8.0). This suspension was centrifuged for 5 min at 3100 x g and 4 °C, and this washing step with Tris-EDTA was repeated nine additional times. After these washing steps, the pellet was resuspended in 150 µL ice-cold water supplemented with 5-10 mM EDTA and centrifuged for 5 min at 3100 x g and 4 °C. This step was performed 3-5 additional times to release amyloid fibrils from the pellet, with EDTA aiding in fibril solubilization.

Electron microscopy of negatively stained samples

Confirmation of amyloid fibril extraction was achieved through negative-stained transmission electron microscopy, following the described protocol²³. In brief, a 3 µL sample was placed on a glow-discharged carbon film 300-mesh copper grid (Electron Microscopy Sciences), incubated for 2 min, and delicately blotted on filter paper to eliminate excess solution. Subsequently, the grid underwent negative staining with 5 µL of 2% uranyl acetate for 2 min, followed by gentle blotting to remove the staining solution. An additional 5 µL of uranyl acetate was applied and promptly removed from the grid. Specimens were examined using an FEI Tecnai 12 electron microscope with an accelerating voltage of 120 kV.

Western blotting of extracted ATTR fibrils

Western blot analysis was conducted on the extracted fibrils to verify their type³³. In summary, 0.5 µg of fibrils were dissolved in a tricine SDS sample buffer, boiled for 2 min at 85 °C, and then ran on a Novex™ 16% tris-tricine gel system using a Tricine SDS running buffer. The type of (TTR) was identified by transferring the gel contents onto a 0.2 µm nitrocellulose membrane and probing it with a primary antibody (1:1000) targeting the C-terminal region of the wild-type TTR sequence from GenScript. A secondary antibody, horseradish peroxidase-conjugated goat anti-rabbit IgG (dilution 1:1000, Invitrogen), was then used. TTR content was visualized using Promega Chemiluminescent Substrate, following the manufacturer's instructions.

Amyloid seeding assay

Extracts of amyloid fibrils were used for seeding the formation of new fibrils from recombinant MTTR as detailed in our previous work³⁴. In summary, the extracts were treated with 1% sodium dodecyl sulfate (SDS) and centrifuged for 1500 x g for 20 min in order to further purify the sample. This purification step was repeated twice, and the soluble fractions were removed. The sample then underwent three washes with sodium phosphate-EDTA (without the addition of 1% SDS) through centrifugation, and was then sonicated in a bath sonicator using a cycle of 5 seconds on and 5 sec off for a duration of 10 min, using a minimum amplitude of 30 (Q700 sonicator, Qsonica). To measure the total protein content in the prepared seeds, the Micro BCA™ Protein Assay Kit (Thermo Fisher Scientific) was used in which a 2% (w/w) seed

solution was added to 0.5 μ g/mL recombinant MTTR in a final volume of 200 μ L, containing 10 μ M thioflavin T (ThT) and 1 \times PBS (pH 7.4). The ThT fluorescence emission was measured at 482 nm with absorption at 440 nm in a FLUOstar Omega (BMG LabTech) microplate reader. The plates (384 Well Optical Btw Plt Polybase Black w/o Lid Non-Treated PS, Thermo Fisher Scientific) were incubated at 37 $^{\circ}$ C with cycles of 9 min shaking (700 rpm double orbital) and 1 min rest throughout the incubation period. Measurements were taken every 10 min (bottom read) with a manual gain of 1000 fold. Confirmation of fibril formation was performed using transmission electron microscopy, as previously described.

Mass Spectrometry (MS) sample preparation, data acquisition and analysis

For tryptic MS analysis, 0.5 μ g of extracted ATTR fibrils were dissolved in a tricine SDS sample buffer, boiled for 2 min at 85 $^{\circ}$ C, then run on a NovexTM 16% tris-tricine gel system using a Tricine SDS running buffer. The gel was then stained with Coomassie dye, destained, and the ATTR smear was excised from the gel. The sample was then submitted for MS analysis. Samples were digested overnight with trypsin (Pierce) following reduction and alkylation with DTT and iodoacetamide (Sigma–Aldrich). The samples then underwent solid-phase extraction cleanup with an Oasis HLB plate (Waters) and the resulting samples were injected onto an Q Exactive HF mass spectrometer coupled to an Ultimate 3000 RSLC-Nano liquid chromatography system. Samples were injected onto a 75 μ m i.d., 15 cm long EasySpray column (Thermo) and eluted with a gradient from 0-28% buffer B over 90 min. Buffer A contained 2% (v/v) ACN and 0.1% formic acid in water, and buffer B contained 80% (v/v) ACN, 10% (v/v) trifluoroethanol, and 0.1% formic acid in water. The mass spectrometer operated in positive ion mode with a source voltage of 2.5 kV and an ion transfer tube temperature of 300 $^{\circ}$ C. MS scans were acquired at 120,000 resolution in the Orbitrap and up to 20 MS/MS spectra were obtained in the ion trap for each full spectrum acquired using higher-energy collisional dissociation (HCD) for ions with charges 2-8. Dynamic exclusion was set for 20 sec after an ion was selected for fragmentation.

Raw MS data files were analyzed using Proteome Discoverer v3.0 SP1 (Thermo), with peptide identification performed using a semitryptic search with Sequest HT against the human reviewed protein database from UniProt. Fragment and precursor tolerances of 10 ppm and 0.02 Da were specified, and three missed cleavages were allowed. Carbamidomethylation of Cys was set as a fixed modification, with oxidation of Met set as a variable modification. The false-discovery rate (FDR) cutoff was 1% for all peptides.

The mass spectrometry proteomics data have been deposited to MassIVE (ProteomeXchange). MassIVE accession number.

Cryo-EM sample preparation, data collection, and processing

A 3.5 μ L aliquot of the freshly-extracted ATTR fibrils were applied to glow-discharged Quantifoil R 1.2/1.3, 300-mesh, Cu grids. The grid was then blotted with filter paper to remove

the excess sample, and plunge frozen into liquid ethane using a Vitrobot Mark IV (FEI). This Cryo-EM sample was screened on the Talos Arctica at the Cryo-Electron Microscopy Facility (CEMF) at University of Texas Southwestern Medical Center (UTSW). Cryo-EM data was collected on a 300 kV Titan Krios microscope (FEI) at the Stanford-SLAC Cryo-EM Center (S²C²) (Supplementary Table 1). All movies were recorded using a Falcon4 camera and EPU software (Thermo Fisher Scientific). All collection parameters are detailed in Supplementary Table 1. Raw movies were gain-corrected, aligned and dose-weighted using RELION's own implemented motion correction program³⁵. Contrast transfer function (CTF) estimation was performed using CTFFIND 4.1³⁶. All steps of helical reconstruction, three-dimensional (3D) refinement, and post-process were carried out using RELION 4.0²². Single filaments were picked automatically using Topaz, while double filaments were picked manually³⁷. Particles were initially extracted using a box size of 768 pixels, then down-scaled to 256 pixels to determine the cross-over distance and the population distribution for each morphology. To further process the data, single filaments and double filaments were extracted in box of 192 pixels and 320 pixels, respectively. Reference-free 2D classification were performed for all datasets to select suitable particles for 3D reconstructions. Fibril helices were assumed to be left-handed. We used an elongated Gaussian blob as an initial reference for 3D classifications of single filaments. For 3D classifications of double filaments, the initial model was generated from 2D class average images using a RELION built-in, script `reliion_helix_inimodel2d`³⁸. We performed 3D classifications to select for the best particles leading to the beset reconstructed maps. 3D auto-refinements and CTF refinements were carried out to obtain higher resolution maps. Final maps were post-processed using the recommended standard procedures in RELION, and the overall resolutions were estimated at threshold of 0.143 in the Fourier shell correlation (FSC) curve between two independently refined half-maps (Supplementary Fig. 4).

Stabilization energy calculation.

The stabilization energy per residue was calculated by the sum of the products of the area buried for each atom and the corresponding atomic solvation parameters³⁹ (Supplementary Fig. 6). The overall energy was calculated by the sum of energies of all residues, and assorted colors were assigned to each residue in the solvation energy map.

Model building

The refined maps of the different morphologies found in this patient were post-processed in RELION before building their models⁴⁰. We used our previously published model of ATTR184S (PDB code 8tdn) as the template to build the model of ATTRV122Δ single fibril. This model was then used as a template for building the double fibrils' models. Residue modification, rigid body fit zone, and real space refine zone were performed to obtain the resulting models using COOT v0.9.8.1⁴¹. All the statistics are summarized in Supplementary Table 1.

Filament tracing

The fibril segments' coordinates (rlCoordinateX and rlCoordinateY) from the final Refine3D were extracted from the relion file run_data.star. These coordinates were used to create XY-graphs, which were then adjusted to align with the dimensions of the respective micrographs. Of note, only the clearly defined fibril segments were considered for reconstruction, excluding any subpar segments. From this method, the positions of these clearly defined segments, particularly when they belong to the same fibril, may appear as intermixed as depicted in Fig. 6.

Acknowledgments

In recognition of the contributions made by the Late Dr. Merril D. Benson, who significantly advanced the understanding of amyloid diseases and provided support to affected families for decades. Special thanks to the patient and family who generously donated tissues, as well as the University of Indiana for providing the material. We thank the UTSW Cryo-Electron Microscopy Facility, the UTSW Structural Biology Laboratory, the UTSW Electron Microscopy Core Facility, the national cryo-EM facilities Stanford-SLAC (project CA60) for instrumentation, technical support, and/or data collection. We thank the UTSW Proteomics core for technical assistance with the proteomics experiments.

Contributions

Conceptualization: L.S., Y.A., B.A.N. Methodology: L.S., Y.A., B.A.N, V.S., S.A. and Investigation: Y.A., B.A.N., V.S., S.A., B.E., R.P., M.P., M.C.F.R., P.B., P.S., and L.W. Visualization: B.A.N., L.S., and Y.A. Funding acquisition: L.S. Project Administration: L.S. Supervision: L.S. Writing—original draft: Y.A., L.S., and B.A.N. Writing—review and editing: L.S, Y.A, B.A.N., and P.B.

Disclosures

L.S. consults for Intellia Therapeutics Inc. and Attralus Inc., and Advisory Board member for Alexion Pharmaceuticals. The remaining authors declare no competing interests.

Funding

American Heart Association, Career Development Award 847236, L.S.
National Institutes of Health, National Heart, Lung, and Blood Institute, New Innovator Award DP2-HL163810, L.S.
Welch Foundation, Research Award I-2121-20220331, L.S.
UTSW Endowment, Distinguished Researcher Award from President's Research Council and start-up funds, L.S.
Junta de Andalucía, EMERGIA20_00276, R.G.P.
National Institutes for Aging, NIH grant R01 AG04812, D.S.E.

Cryo-EM research was partially supported by the following grants:
National Institutes of Health grant U24GM129547, Department of Energy Office of Science User Facility sponsored by the Office of Biological and Environmental Research

Department of Energy, Laboratory Directed Research and Development program at SLAC
National Accelerator Laboratory, under contract DE-AC02-76SF00515
NIH Common Fund Transformative High Resolution Cryo-Electron Microscopy program (U24
GM129539)

The Cryo-Electron Microscopy Facility and the Structural Biology Laboratory at UTSW are
supported by a grant from the Cancer Prevention & Research Institute of Texas (RP170644).

The Electron Microscopy Core Facility at UTSW is supported by the National Institutes of
Health (NIH) (1S10OD021685-01A1 and 1S10OD020103-01).

Part of the computational resources were provided by the BioHPC supercomputing facility
located in the Lyda Hill Department of Bioinformatics at UTSW. URL:

<https://portal.biohpc.swmed.edu>.

References:

- 1 Buxbaum, J. N. & Reixach, N. Transthyretin: the servant of many masters. *Cellular and Molecular Life Sciences* **66**, 3095-3101 (2009). <https://doi.org/10.1007/s00018-009-0109-0>
- 2 Bezerra, F., Saraiva, M. J. & Almeida, M. R. Modulation of the Mechanisms Driving Transthyretin Amyloidosis. *Frontiers in Molecular Neuroscience* **13** (2020). <https://doi.org/10.3389/fnmol.2020.592644>
- 3 Ando, Y. *et al.* Guideline of transthyretin-related hereditary amyloidosis for clinicians. *Orphanet Journal of Rare Diseases* **8**, 31 (2013). <https://doi.org/10.1186/1750-1172-8-31>
- 4 Rowczenio, D. M. *et al.* Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations. *Human Mutation* **35**, E2403-E2412 (2014). <https://doi.org/10.1002/humu.22619>
- 5 He, S. *et al.* The Structural Understanding of Transthyretin Misfolding and the Inspired Drug Approaches for the Treatment of Heart Failure Associated With Transthyretin Amyloidosis. *Frontiers in Pharmacology* **12** (2021). <https://doi.org/10.3389/fphar.2021.628184>
- 6 Dasari, A. K. R. *et al.* Transthyretin Aggregation Pathway toward the Formation of Distinct Cytotoxic Oligomers. *Scientific Reports* **9** (2019). <https://doi.org/10.1038/s41598-018-37230-1>
- 7 Abskharon, R. *et al.* Cryo-EM structure of RNA-induced tau fibrils reveals a small C-terminal core that may nucleate fibril formation. *Proceedings of the National Academy of Sciences* **119** (2022). <https://doi.org/10.1073/pnas.2119952119>
- 8 Cao, Q. *et al.* Cryo-EM structures of hIAPP fibrils seeded by patient-extracted fibrils reveal new polymorphs and conserved fibril cores. *Nature Structural & Molecular Biology* **28**, 724-730 (2021). <https://doi.org/10.1038/s41594-021-00646-x>
- 9 Wang, L.-Q. *et al.* Cryo-EM structure of an amyloid fibril formed by full-length human prion protein. *Nature Structural & Molecular Biology* **27**, 598-602 (2020). <https://doi.org/10.1038/s41594-020-0441-5>
- 10 Falcon, B. *et al.* Structures of filaments from Pick's disease reveal a novel tau protein fold. *Nature* **561**, 137-140 (2018). <https://doi.org/10.1038/s41586-018-0454-y>
- 11 Falcon, B. *et al.* Tau filaments from multiple cases of sporadic and inherited Alzheimer's disease adopt a common fold. *Acta Neuropathologica* **136**, 699-708 (2018). <https://doi.org/10.1007/s00401-018-1914-z>
- 12 Schweighauser, M. *et al.* Structures of α -synuclein filaments from multiple system atrophy. *Nature* **585**, 464-469 (2020). <https://doi.org/10.1038/s41586-020-2317-6>
- 13 Yang, Y. *et al.* Structures of α -synuclein filaments from human brains with Lewy pathology. *Nature* **610**, 791-795 (2022). <https://doi.org/10.1038/s41586-022-05319-3>
- 14 Arseni, D. *et al.* Structure of pathological TDP-43 filaments from ALS with FTLD. *Nature* **601**, 139-143 (2022). <https://doi.org/10.1038/s41586-021-04199-3>
- 15 Falcon, B. *et al.* Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules. *Nature* **568**, 420-423 (2019). <https://doi.org/10.1038/s41586-019-1026-5>
- 16 Schmidt, M. *et al.* Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. *Nat Commun* **10**, 5008 (2019). <https://doi.org/10.1038/s41467-019-13038-z>

- 17 Nguyen, B. A. *et al.* Cryo-EM confirms a common fibril fold in the heart of four patients with ATTRwt amyloidosis. *bioRxiv* (2024). <https://doi.org/10.1101/2024.03.08.582936>
- 18 Nguyen, B. A. *et al.* Structural polymorphism of amyloid fibrils in ATTR amyloidosis revealed by cryo-electron microscopy. *Nature Communications* **15** (2024). <https://doi.org/10.1038/s41467-024-44820-3>
- 19 Iakovleva, I. *et al.* Structural basis for transthyretin amyloid formation in vitreous body of the eye. *Nat Commun* **12**, 7141 (2021). <https://doi.org/10.1038/s41467-021-27481-4>
- 20 Uemichi, T., Liepnieks, J. J. & Benson, M. D. A trinucleotide deletion in the transthyretin gene (delta V 122) in a kindred with familial amyloidotic polyneuropathy. *Neurology* **48**, 1667-1670 (1997).
- 21 Suhr, O. B., Lundgren, E. & Westermark, P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. *J Intern Med* **281**, 337-347 (2017). <https://doi.org/10.1111/joim.12585>
- 22 Kimanius, D., Dong, L., Sharov, G., Nakane, T. & Scheres, S. H. W. New tools for automated cryo-EM single-particle analysis in RELION-4.0. *Biochem J* **478**, 4169-4185 (2021). <https://doi.org/10.1042/BCJ20210708>
- 23 Nguyen, B. A. *et al.* Structural polymorphism of amyloid fibrils in ATTR amyloidosis revealed by cryo-electron microscopy. *Nat Commun* **15**, 581 (2024). <https://doi.org/10.1038/s41467-024-44820-3>
- 24 Iakovleva, I. *et al.* Structural basis for transthyretin amyloid formation in vitreous body of the eye. *Nat Commun* **12**, 7141 (2021). <https://doi.org/10.1038/s41467-021-27481-4>
- 25 Steinebrei, M. *et al.* Common transthyretin-derived amyloid fibril structures in patients with hereditary ATTR amyloidosis. *Nat Commun* **14**, 7623 (2023). <https://doi.org/10.1038/s41467-023-43301-3>
- 26 Steinebrei, M. *et al.* Cryo-EM structure of an ATTRwt amyloid fibril from systemic non-hereditary transthyretin amyloidosis. *Nat Commun* **13**, 6398 (2022). <https://doi.org/10.1038/s41467-022-33591-4>
- 27 Schmidt, M. *et al.* Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis. *Nat Commun* **10**, 5008 (2019). <https://doi.org/10.1038/s41467-019-13038-z>
- 28 Radamaker, L. *et al.* Cryo-EM reveals structural breaks in a patient-derived amyloid fibril from systemic AL amyloidosis. *Nature Communications* **12**, 875 (2021).
- 29 Foss, T., Wiseman, R. & Kelly, J. The pathway by which the tetrameric protein transthyretin dissociates. *Biochemistry* **44**, 15525-15533 (2005). <https://doi.org/10.1021/bi051608t>
- 30 Johnson, S. *et al.* Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. *Acc Chem Res* **38**, 911-921 (2005). <https://doi.org/10.1021/ar020073i>
- 31 Schonhoft, J. *et al.* Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients. *Sci Transl Med* **9** (2017). <https://doi.org/10.1126/scitranslmed.aam7621>
- 32 Pedretti R, W. L., Hanna M, Grodin J, Tang WH, Masri A, Saelices L. Detection of circulating transthyretin amyloid aggregates in plasma: a novel biomarker for transthyretin amyloidosis. *Circulation* **in press** (2024). <https://doi.org/10.1161/CIRCULATIONAHA.123.067225>

- 33 Ihse, E., Suhr, O., Hellman, U. & Westermark, P. Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis. *J Mol Med (Berl)* **89**, 171-180 (2011). <https://doi.org/10.1007/s00109-010-0695-1>
- 34 Saelices, L. *et al.* Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition. *Proc Natl Acad Sci U S A* **115**, E6741-E6750 (2018). <https://doi.org/10.1073/pnas.1805131115>
- 35 Zivanov, J., Nakane, T. & Scheres, S. H. W. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. *IUCrJ* **7**, 253-267 (2020). <https://doi.org/10.1107/S2052252520000081>
- 36 Rohou, A. & Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. *J Struct Biol* **192**, 216-221 (2015). <https://doi.org/10.1016/j.jsb.2015.08.008>
- 37 Bepler, T. *et al.* Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. *Nat Methods* **16**, 1153-1160 (2019). <https://doi.org/10.1038/s41592-019-0575-8>
- 38 Scheres, S. Amyloid structure determination in RELION-3.1. *Acta Crystallogr D Struct Biol* **76**, 94-101 (2020). <https://doi.org/10.1107/S2059798319016577>
- 39 Sawaya, M., Hughes, M., Rodriguez, J., Riek, R. & Eisenberg, D. The expanding amyloid family: Structure, stability, function, and pathogenesis. *Cell* **184**, 4857-4873 (2021). <https://doi.org/10.1016/j.cell.2021.08.013>
- 40 Terwilliger, T., Sobolev, O., Afonine, P. & Adams, P. Automated map sharpening by maximization of detail and connectivity. *Acta Crystallogr D Struct Biol* **74**, 545-559 (2018). <https://doi.org/10.1107/S2059798318004655>
- 41 Emsley, P., Lohkamp, B., Scott, W. & Cowtan, K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* **66**, 486-501 (2010). <https://doi.org/10.1107/S0907444910007493>